EICHOR
● Completed
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
Condition: Tetanus · Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.
About this study
The primary objective is to compare the anti-tetanus neutralizing antibody titers of TNM002 Injection with human tetanus immunoglobulin (HTIG) following a single intramuscular (IM) injection in Chinese adult volunteers.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (4)
| The First Affiliated Hospital of Shantou University Medical College | Shantou, Guangdong, China | — |
| Wuxi People's Hospital | Wuxi, Jiangsu, China | — |
| PKUCare Luzhong Hospital | Zibo, Shandong, China | — |
| Yunnan Provincial Hospital of Traditional Chinese Medicine | Kunming, Yunnan, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05625477